Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
J Mal Vasc ; 40(1): 10-7, 2015 Feb.
Artigo em Francês | MEDLINE | ID: mdl-25631643

RESUMO

AIM: Masked hypertension (MH) is defined by a normal office blood pressure (BP) and a high ambulatory BP. MH is characterized by high prevalence and poor cardiovascular prognosis. The aim of this study was to evaluate the usefulness of routine MH screening, using 24-h blood pressure monitoring (BPM), among patients with peripheral arterial disease (PAD). METHODS: Between 2011 and 2013, 54 patients with PAD were included in the Hypertension and Vascular Medicine Unit of the Lille Hospital. They had normal office BP (< 140/90mmHg). A 24 h-BPM device was set on each patient. MH diagnosis was established if the BP average over 24 hours was ≥ 130/80 mmHg and/or the daytime average ≥ 135/85 mmHg and/or the nighttime average ≥ 120/70 mmHg. RESULTS: MH prevalence was about 42.6% (23 patients). It was significantly more frequent in diabetic patients (odds ratio: 3.8 [1.1-12.8]), in patients with known hypertension (odds ratio: 5 [1.5-16.9]) or with high normal office BP (<140/90 mmHg but ≥ 130/85 mmHg) (odds ratio: 5.6 [1.7-18.2]). By multivariate analysis, only known hypertension and high normal office BP were associated with masked hypertension. CONCLUSION: The high prevalence of MH in patients with PAD shows us the importance of a careful screening of MH in this population, especially in diabetic patients, in patients with known hypertension or with a high normal office BP.


Assuntos
Hipertensão Mascarada/diagnóstico , Doença Arterial Periférica/complicações , Doença Arterial Periférica/fisiopatologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Pressão Sanguínea , Monitorização Ambulatorial da Pressão Arterial , Complicações do Diabetes/epidemiologia , Diabetes Mellitus/fisiopatologia , Feminino , França/epidemiologia , Humanos , Masculino , Hipertensão Mascarada/epidemiologia , Programas de Rastreamento , Pessoa de Meia-Idade , Razão de Chances , Projetos Piloto
2.
J Vet Intern Med ; 24(5): 1077-85, 2010.
Artigo em Inglês | MEDLINE | ID: mdl-20666982

RESUMO

BACKGROUND: Adrenal ultrasonography (US) in dogs with hyperadrenocorticism (HAC) is commonly used to distinguish adrenocorticotropic hormone (ACTH)-independent (AIHAC) and ACTH-dependent hyperadrenocorticism (ADHAC). To date, no cut-off values for defining adrenal atrophy in cases of adrenal asymmetry have been determined. Given that asymmetrical hyperplasia is sometimes observed in ADHAC, adrenal asymmetry without ultrasonographic proof of adrenocortical tumor such as vascular invasion or metastasis can be equivocal. OBJECTIVE: The purpose of this study was to compare adrenal US findings between cases of ADHAC and AIHAC in dogs with equivocal adrenal asymmetry (EAA), and to identify useful criteria for their distinction. ANIMALS: Forty dogs with EAA were included. METHODS: Ultrasound reports of HAC dogs with adrenal asymmetry without obvious vascular invasion or metastases were reviewed. Dogs were classified as cases of ADHAC (n = 28) or AIHAC (n = 19), determined by plasma ACTH concentration. The thickness, shape, and echogenicity of both adrenal glands and presence of adjacent vascular compression were compared between AIHAC and ADHAC groups. RESULTS: The maximal dorsoventral thickness of the smaller gland (SDV) ranged from 2.0 to 5.0 mm in AIHAC and from 5.0 to 15.0 mm in ADHAC. The 95% confidence intervals for estimated sensitivity and specificity of a SDV cut-off set at 5.0 mm in the diagnosis of AIHAC were 82-100 and 82-99%, respectively. Other tested US criteria were found to overlap extensively between the 2 groups, precluding their usefulness for distinction. CONCLUSION AND CLINICAL IMPORTANCE: In EAA cases, an SDV ≤5.0 mm is an appropriate cut-off for AIHAC ultrasonographic diagnosis.


Assuntos
Glândulas Suprarrenais/patologia , Hiperfunção Adrenocortical/veterinária , Hormônio Adrenocorticotrópico/metabolismo , Doenças do Cão/diagnóstico por imagem , Glândulas Suprarrenais/diagnóstico por imagem , Hiperfunção Adrenocortical/diagnóstico , Hiperfunção Adrenocortical/diagnóstico por imagem , Hiperfunção Adrenocortical/tratamento farmacológico , Hormônio Adrenocorticotrópico/farmacologia , Animais , Dexametasona/farmacologia , Doenças do Cão/diagnóstico , Doenças do Cão/patologia , Cães , Estudos Retrospectivos , Ultrassonografia
3.
J Anim Physiol Anim Nutr (Berl) ; 85(7-8): 242-50, 2001 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-11686796

RESUMO

Observations on food tolerance in dogs have shown that some breeds, especially the giant breeds, have a greater digestive sensitivity. One of the consequences common in these breeds is a higher faecal water content and a poor faecal quality. This could be explained, at least in part, by limited digestive capacity and function in giant breed dogs. In this report, the gastric emptying that represents one parameter of the digestive function was studied in large and giant breed dogs during their growth. Six Great Danes (GD) and six Giant Schnauzers (GS) were fed small radiopaque markers mixed with a test diet at 12, 22 and 36 weeks of age. Abdominal radiographs were made every 30 min for a period of 4 h and then hourly until 12 h. At 12 weeks of age, the gastric emptying pattern was similar in both breeds. However, from 22 weeks of age, the gastric emptying of the GD was significantly more rapid than that of GS. The gastric emptying of small markers tended to slow down in growing dogs, especially in GS. A significant positive correlation between the gastric emptying time of 50% of markers and the body weight was found. These results show that GD have a lower gastric retention time of foods, which could lead to a poor digestion and an altered absorption of nutrients. These could explained why digestive function and sensitivity could be different in dogs from different sizes and breeds.


Assuntos
Cães/fisiologia , Esvaziamento Gástrico/fisiologia , Trânsito Gastrointestinal/fisiologia , Intestino Grosso/fisiologia , Intestino Delgado/fisiologia , Fatores Etários , Ração Animal , Animais , Biomarcadores/análise , Constituição Corporal/fisiologia , Peso Corporal/fisiologia , Dieta/veterinária , Cães/metabolismo , Feminino , Intestino Grosso/metabolismo , Intestino Delgado/metabolismo , Radiografia Abdominal/métodos , Radiografia Abdominal/veterinária , Fatores de Tempo
4.
Bone Marrow Transplant ; 25(9): 937-42, 2000 May.
Artigo em Inglês | MEDLINE | ID: mdl-10800060

RESUMO

Although infants with stage 4 neuroblastoma (NB) usually have a good prognosis, metastatic relapses after 1 year of age and amplification of the N-myc oncogene are established poor prognostic factors. In order to improve the survival of patients with such high-risk factors, we performed consolidation with a busulfan (600 mg/m2)-melphalan (140 mg/m2)-containing regimen followed by autologous stem cell transplantation (SCT). From 1986 to 1998, 12 patients were treated according to this strategy. Their median age at diagnosis was 9 months (1-11). Consolidation was performed after a metastatic relapse in five children, because of persistent bone metastases in one and as first-line consolidation in six patients whose tumor exhibited N-myc amplification. The 5-year EFS rate is 64. 5% (36-85%) with a median follow-up of 92 months (20-126). One toxicity-related death occurred in a very heavily pretreated patient. Hepatic veno-occlusive disease was the major side-effect that occurred in nine of 12 children. This busulfan-melphalan combination appears to dramatically improve the prognosis of these high-risk infants with metastatic NB. Given its high toxicity, indications for this consolidation must be restricted to high-risk infants and a lower dose of busulfan (480 mg/m2) is recommended in children weighing less than 10 kg. Bone Marrow Transplantation (2000) 25, 937-942.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Neoplasias Encefálicas/terapia , Bussulfano/administração & dosagem , Transplante de Células-Tronco Hematopoéticas , Imunossupressores/administração & dosagem , Neuroblastoma/terapia , Peso Corporal , Neoplasias Encefálicas/patologia , Terapia Combinada , Humanos , Lactente , Melfalan/administração & dosagem , Neuroblastoma/patologia , Prognóstico , Análise de Sobrevida , Transplante Autólogo
6.
Eur J Clin Microbiol Infect Dis ; 18(10): 726-8, 1999 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-10584900

RESUMO

Reported here is the case of a 9-year-old girl presenting with disseminated tuberculosis, the manifestations of which included mediastinal adenopathy, an osteolytic parietal lesion with a large associated scalp abscess, cerebral empyema, meningoencephalitis, and tuberculomas. No clear improvement was observed after 4 weeks of first-line antituberculosis treatment (10 mg/kg rifampin, 15 mg/kg isoniazid, 30 mg/kg ethambutol, 30 mg/kg pyrazinamide). The isolation of an isoniazid-resistant organism prompted institution of ofloxacin. Introduction of this drug was associated with dramatic improvement. Its good penetration into the central nervous system and its distribution into macrophages suggest that this drug may be of interest for the treatment of intracranial tuberculomas, particularly those due to isoniazid-resistant strains.


Assuntos
Anti-Infecciosos/uso terapêutico , Ofloxacino/uso terapêutico , Tuberculoma Intracraniano/tratamento farmacológico , Criança , Feminino , Humanos
7.
J Small Anim Pract ; 37(8): 367-70, 1996 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-8872936

RESUMO

Simultaneous insulin and glucose measurements from a single sample are often insufficient for the laboratory diagnosis of insulinoma in the hypoglycaemic dog. Although the simple insulin (microU/litre): glucose (mmol/litre) ratio is best, when the selected threshold is set at 13.5, it is not always efficient to confirm or refute insulinoma. The fasting test consists of collecting four samples on a given day (no accurate time period is set between any two samples) from a fasting dog for simultaneous insulin and glucose measurements to detect at least one abnormal insulinaemia peak.


Assuntos
Testes Diagnósticos de Rotina/veterinária , Doenças do Cão/diagnóstico , Cães/sangue , Insulinoma/veterinária , Neoplasias Pancreáticas/veterinária , Animais , Glicemia/análise , Doenças do Cão/sangue , Hipoglicemia/sangue , Hipoglicemia/veterinária , Insulina/sangue , Insulinoma/sangue , Insulinoma/diagnóstico , Neoplasias Pancreáticas/sangue , Neoplasias Pancreáticas/diagnóstico , Estudos Retrospectivos , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA